ArticleObstetrics & gynecology science2024
Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer.
Yutaka Yoneoka et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.